To make things easier, leave this box checked On shared devices, we recommend that you disconnect from Euroquity when you are done
Email

You will receive an email to define a new password

Location

Select your country

and your language

Hi ,

Welcome to your personnel profile page! Fill in your information in order to become more visible to organizations that interest you.

% completed

%

medal 2
This profile is validated by 2 label.

Company

MONA

MONA_logo
43
EQ SCORE

The EQ Score shows the company's activity and appeal on the platform: profile completeness, news, likes, follows, membership in one or more labels or communities, number of members in its network, etc.

Blindness prevention with a complete digital health solution, powered with artificial intelligence to screen for diabetic retinopathy and glaucoma. Spin off from 2 Belgian research institutions VITO and Catholic University of Leuven

Mol, Région flamande, Belgium

Send a message

  • 2

    employees

  • €1

    turnover

English

MONA

English

MONA is a spin off from the Catholic University of Leuven and the Belgian research institute VITO.

MONA develops a solution to diagnose eye diseases from retinal pictures with artificial intelligence. It is a full solution with an automated retinal camera linked to artificial intelligence.

The Team

Co founders :

Pr Ingeborg Stalmans : Professor, Head of the Glaucoma Unit and Director of Ophthalmology Research Center, KUL

...
See more

MONA is a spin off from the Catholic University of Leuven and the Belgian research institute VITO.

MONA develops a solution to diagnose eye diseases from retinal pictures with artificial intelligence. It is a full solution with an automated retinal camera linked to artificial intelligence.

The Team

Co founders :

Pr Ingeborg Stalmans : Professor, Head of the Glaucoma Unit and Director of Ophthalmology Research Center, KUL

Dr Olivier Ménage :  25 years medical device experience in EMEA

The Problem

4 out of 10 are at risk to become blind if they don't see an ophthalmologist annually.

All diabetics are at risk of diabetic retinopathy, 30% of them suffer from it.

3% of elderly over 50 suffer from glaucoma, only 50% are diagnosed.

Ophthalmologists face long waiting lists, up to 6 months to get an appointment. Glaucoma screening is not even recommended due to the lack of resources needed.

The Solution with MONA

MONA is a self-screening solution, that allows patients to take pictures of their retina and to get

rapidly some advice to refer or not to an ophthalmologist for suspicion of diabetic retinopathy or glaucoma.

No appointment needed. The MONA kiosks will be available first in the diabetes clinics.

Uniqueness

MONA combines the first self-screening retinal camera with the efficiency of artificial intelligence. The business model is a pay per patient, that includes the loan of the kiosk with the retinal camera, no investment nor personnel needed from the hospital

  • 1

    Followers

  • 2

    Like

Our latest news

Team member(s)

Your request has been sent
Join this organization
Your request has been sent

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

ePitches EuroQuity
193 Entities
Start it @KBC
3 Entities

Communities

EUROQUITY BELGIUM
EuroQuity Belgium AT THE SERVICE OF BUSINESS GROWTH The community is reserved for growing Belgian companies and their partners: investors and business partners.
889 Members
France Angels
France Angels is a Nationale Federation of Business Angels. Nationale federation that federates, represents and promotes French Business Angels.
431 Members
ESIL - Early Stage Investing Launchpad
Early Stage Investing Launchpad has the overall objective of developing and boosting the activities for Business Angels through an international capacity building program
438 Members

Our history

Start in Nov 2020 EClair Clinical trial

  • Nov 2020 EClair Clinical trial

    Diabetes Liga funded our clinical trial to include 1200 patients in 3 hospitals in Belgium

  • 2016 Iflexis

    Vito launched a software to measure the size of retinal vesses

to be continued ...